Logo-jnp
Short-Review

1. Is it the time to offer rituximab as a cost-benefit treatment for immunoglobulin A nephropathy? A short-review to current concepts
Mohammad-Reza Tamadon, Jamileh Moghimi*, Hamed Rezaei
J Nephropathol. 2018;7(1): 7-10. doi: 10.15171/jnp.2018.03
Scopus ID: 85041132636    
Article
PDF
XML
Cited By:
0
0